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Abstract
Several experimental strategies of radiation-induced central nervous system toxicity prevention
have recently resulted in encouraging data. The present review summarizes the background for this
research and the treatment results. It extends to the perspectives of tissue regeneration strategies,
based for example on stem and progenitor cells. Preliminary data suggest a scenario with
individually tailored strategies where patients with certain types of comorbidity, resulting in
impaired regeneration reserve capacity, might be considered for toxicity prevention, while others
might be "salvaged" by delayed interventions that circumvent the problem of normal tissue
specificity. Given the complexity of radiation-induced changes, single target interventions might not
suffice. Future interventions might vary with patient age, elapsed time from radiotherapy and
toxicity type. Potential components include several drugs that interact with neurodegeneration, cell
transplantation (into the CNS itself, the blood stream, or both) and creation of reparative signals
and a permissive microenvironment, e.g., for cell homing. Without manipulation of the stem cell
niche either by cell transfection or addition of appropriate chemokines and growth factors and by
providing normal perfusion of the affected region, durable success of such cell-based approaches is
hard to imagine.
Background
The risk of permanent central nervous system (CNS) tox-
icity, which typically becomes detectable after an asymp-
tomatic latency period, continues to influence clinical
treatment decisions. Interindividual differences in sensi-
tivity result in a certain variability of the threshold dose
and preclude administration of a guaranteed safe dose,
even in the current era of high-precision image-guided
radiotherapy. The easiest and most effective way of avoid-
ing CNS side effects is to minimize the dose of radiation.
This does, however, not solve the problem of normal tis-
sue present within the target volume, for example due to
diffuse microscopic spread, which escapes current imag-
ing technology. For certain groups of patients, further
progress can only be expected from efforts directed at wid-
ening the therapeutic window between tumor and normal
tissue through specific modulation of their responses to
radiotherapy (e.g., toxicity prevention) or from delayed
intervention such as tissue regeneration strategies. Both
prevention and treatment of side effects have their specific
advantages and disadvantages. Importantly, they are not
standard clinical options at this time. To exploit potential
targets for intervention, we will discuss the pathogenesis
of radiation-induced CNS toxicity and review preclinical
data on prevention and tissue regeneration. We focus on
two types of damage, i.e. neurocognitive decline and radi-
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ation necrosis. The latter is relevant to treatment of the
brain and the spinal cord.
Pathogenesis
Initial evaluations of radiation-induced CNS toxicity date
back at least 70 years ago. These historical data have been
summarized in previous reviews, for example by van der
Kogel [1] and Schultheiss et al. [2]. In brief, previous
experimental studies indicated that signs of diffuse demy-
elination develop in animals 2 weeks after CNS radiother-
apy. After approximately 2 months, remyelination
processes were observed. These early changes correspond
to clinical symptoms such as Lhermitte's sign and somno-
lence in humans. After a variable latency period, and
dependent on total dose, white matter necrosis might
develop. The grey matter is less sensitive. Latency time
decreases with increasing radiation dose. The most impor-
tant determinants of CNS tolerance are the volume of nor-
mal tissue exposed, dose per fraction and total dose.
Overall treatment time is less important. With multiple
fractions per day, incomplete repair needs to be taken into
account, especially when the interfraction interval is less
than 6 h. When high focal doses are combined with lower
doses to a large surrounding volume, tolerance decreases
compared to the same focal treatment alone.
Significant long-term recovery has been observed after spi-
nal cord radiotherapy. Although not experimentally tested
in the same fashion, it can be assumed that the brain
recovers too. Especially with larger intervals of at least 1–
2 years and when the first treatment course was not too
close to tolerance, re-irradiation is now considered as a
realistic option. Experimental data from fractionated radi-
otherapy of rhesus monkeys suggest that up to 75% of ini-
tial damage recover within 2–3 years [3]. Increasing
clinical evidence supports the feasibility of re-irradiation
in selected patients [4].
The last years have witnessed a significant improvement
of techniques in cellular and molecular biology, resulting
for example in description of more and more radiobio-
logically relevant signalling pathways [5]. Advanced
methods for identification of stem and progenitor cells
were developed. Meanwhile, this progress has led to a bet-
ter understanding of tissue responses to ionizing radia-
tion. Obviously, radiation-induced reactions of the CNS
include death of both immature and mature parenchymal
and vascular cell populations, executed via different
mechanisms at different time points. Apoptosis induced
by sphingomyelinase-mediated release of ceramide has
been described as early reaction in endothelial cells within
the irradiated CNS [6,7] as well as in oligodendrocytes [8].
Current models of radiation-induced changes include a
cascade of complex and dynamic interactions between
mature parenchymal cells (oligodendrocytes, astrocytes,
microglia, neurons), stem and progenitor cells and the
vascular system, also resulting in important alterations of
the local microenvironment [9]. The latent time preceding
the clinical manifestation of damage is viewed as an active
phase where chemokines, cytokines and growth factors
play important roles in intra- and intercellular communi-
cation.
CNS radiotherapy induces the production of inflamma-
tory cytokines and mediators such as tumor-necrosis-fac-
tor-α (TNF-α), interleukin-1 (IL-1), and prostaglandin E2
by microglia and astrocytes [10-12]. Some of these facili-
tate transendothelial migration of immune cells. IL-1
release leads, via autocrine mechanisms, to further activa-
tion and proliferation of these glia cells. As shown in vivo,
this cascade results in astrogliosis [13]. Furthermore,
inflammatory microenvironmental changes can impair
the compensation of the radiation-induced cell loss. TNF-
α is also known to damage endothelial cells, leading to
increased vascular permeability. TNF-α and IL-1 induce
the expression of intercellular adhesion molecule-1
(ICAM-1) on oligodendrocytes and microvascular
endothelial cells [14,15]. Increased levels of ICAM-1
mRNA were detectable after midbrain irradiation with 2
Gy [16]. Results of localized single-fraction treatment
with 20 Gy confirm the presence of an early inflammatory
response, increased numbers of leukocytes, increased vas-
cular permeability, altered integrity of endothelial tight
junctions and increased cell adhesion [17,18]. Injection of
an anti-ICAM-1 monoclonal antibody significantly
reduced leukocyte adhesion and permeability in this
model. The role and time course of inflammatory media-
tors varies with fraction size. Certainly, the cellular and
molecular events during the latent phase require further
research. The role of TNF, for example, might be more
complex than initially thought. In some models, this
cytokine mediates antioxidant defense mechanisms and is
able to induce antiapoptotic proteins such as Bcl-2. Fur-
thermore, TNF-receptor-p75 knockout mice were more
sensitive against radiation-induced brain damage than
control mice and TNF-receptor-p55 knockouts [19].
Special aspects of neurocognitive deficits
Phenomena such as intellectual decline and memory loss
in the absence of gross perfusion disturbance suggest that
neuronal cells react to radiotherapy. Experimental studies
have demonstrated that neurons and precursor cells might
undergo apoptosis after radiotherapy [20]. Fractionated
brain irradiation inhibited the formation of new neurons
in the dentate gyrus of the hippocampus in rats [21]. Ani-
mals with blocked neurogenesis performed poorer in
short-term memory tests which are related to hippocam-
pal function. The deficit in neurogenesis is based on both
reduced proliferative capacity of progenitor cells and alter-
ations in the microenvironment that regulates progenitorRadiation Oncology 2007, 2:23 http://www.ro-journal.com/content/2/1/23
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cell fate (disruption of the microvascular angiogenesis,
activation of microglia) [22]. After higher doses of whole-
brain radiotherapy (WBRT, 8 fractions of 5 Gy) in rats,
cognitive impairment arose after a significant loss of brain
capillaries [23], suggesting once more a multifactorial
pathogenesis. The latter might also include changes in
hippocampal glutamate receptor composition, as recently
suggest by Shi et al. [24].
Special aspects of radiation necrosis of the brain and 
spinal cord
Initial events are similar to those described in the patho-
genesis section, including inflammatory changes and
increased vessel permeability. Studies of boron-neutron-
capture therapy (BNCT) support the view that vascular
damage is one of the crucial components leading to radi-
ation necrosis after higher doses. By choosing boron-com-
pounds which are unable to cross the blood-brain barrier,
a largely selective irradiation of the vessel walls can be
accomplished with BNCT. Compared to conventional
non-selective radiotherapy methods, spinal cord lesions
with similar histological appearance were induced.
Latency time also was comparable between damage
induced by BNCT and conventional radiotherapy [25,26].
Additional evidence is provided by histological examina-
tions of rat brains after radiotherapy with 22.5 or 25 Gy,
showing reduced numbers of blood vessels and endothe-
lial cells before manifestation of necrosis [27]. A study in
rats (partial brain irradiation with 40 or 60 Gy or WBRT
with 25 Gy) showed a 15% reduction in endothelial cell
number between 24 h and 4 weeks after radiotherapy. A
further reduction was seen with even longer intervals [28].
Theses changes are accompanied by hyperpermeability,
resulting in perivascular edema and consecutive ischemic
damage [29].
Kamiryo et al. showed how the latency to development of
vascular damage after stereotactic radiosurgery (SRS) to
the parietal cortex of rat brain decreases from 12 months
to 3 weeks with an increase in radiation dose from 50 to
75 or 120 Gy [30]. The amount of vessel dilation,
increased permeability, thickening of the vessel wall, ves-
sel occlusion and necrosis also increased with dose. Spinal
cord data suggest an increase in the release of vascular
endothelial growth factor (VEGF) as a result of impaired
perfusion and hypoxia signalling [31]. Obviously, the
clinically observed latent phase is characterised by persist-
ent and increasing oxidative stress and active responses to
this factor.
Clinical confirmatory data
Sustaining toxicity that may impair the patients' lifestyle
significantly can be observed several years after radiother-
apy in form of radionecrosis and cognitive dysfunction
associated with leukoencephalopathy. Necrosis develops
mostly after 1–3 years [32]. The typical finding is coagula-
tion necrosis in the white matter with largely normal
appearance of the cortex. Fibrinoid necrosis and
hyalinous wall thickening of blood vessels are commonly
observed. Therapeutic intervention with corticosteroids or
anticoagulants is sometimes successful. Often, surgical
resection is the only way to effectively improve the symp-
toms.
Diffuse white matter changes are frequently observed in
imaging studies. Fluid-attentuated inversion recovery
(FLAIR) and diffusion-weighted MRI might improve visu-
alization of white matter abnormalities, which are not
necessarily associated with clinical symptoms but often
present after fractionated doses of ≥ 30 Gy. Neuropsycho-
logical sequelae typically manifest within 4 years from
radiotherapy. Psychometric findings suggest greater vul-
nerability of white matter and subcortical structures
resulting in reduced processing speed, heightened dis-
tractability and memory impairment. Within the tempo-
ral lobe, the hippocampal formation plays a central role
in short-term memory and learning. These functions are
related to the activity of neural stem cells. The hippocam-
pal granule cell layer undergoes continuous renewal and
restructuring. Radiotherapy can affect this sensitive cell
layer leading to impaired function without overt patho-
logical changes.
There is increasing evidence that partial brain radiother-
apy alone rarely causes significant neurocognitive decline
[33,34]. One of the largest comparative studies in low-
grade glioma showed poorer cognitive function in irradi-
ated patients [35]. However, cognitive disability was asso-
ciated to fraction doses exceeding 2 Gy. In addition,
antiepileptic drug use was strongly associated with disa-
bility in attentional and executive function. The risk of
toxicity might also increase with age, probably as a result
of impaired tissue reserve capacity and perfusion.
Increased sensitivity of children might be related to condi-
tions in the immature CNS, e.g., increased proliferation.
Neurocognitive dysfunction was reported to stabilize
spontaneously [36] or to progress over time [37]. In
extreme cases, subcortical dementia might result which
often is associated with gait disturbance and inconti-
nence. Due to the lack of effective treatment, most
patients with this severe complication die after several
months or a few years. Histopathologic findings include
diffuse spongiosis and demyelination as well as dissimi-
nated miliar necrosis.
Prevention strategies
At present, pharmacologic or biologic prevention
approaches are still considered experimental, despite of
some non-randomized trials, e.g., of SRS for arteriov-
enous malformations where patients treated with gammaRadiation Oncology 2007, 2:23 http://www.ro-journal.com/content/2/1/23
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linolenic [omega-6-] acid had less permanent complica-
tions than those who did not receive this medication [38].
However, several rational experimental interventions
based on the pathogenetic models reviewed earlier have
been studied or are currently under investigation. The
clinical effectiveness of these putative prevention strate-
gies has yet to be established.
On the one hand, the multifactorial pathogenesis offers
many different targets for intervention [39], on the other
hand targeting just one of these complex cascades might
not be sufficient to effectively inhibit tissue degeneration.
Figure 1 illustrates that early intervention has to deal with
functional rather than structural and clinically manifest
damage. While early-stage damage might be easier to
treat, any intervention faces the challenge of selectivity or
the risk of tumor protection. Among the earliest events
that might be targeted are direct and indirect radiation
effects leading to DNA damage. Indirect effects, mediated
via reactive oxygen species, can be counteracted by radical
scavengers such as amifostine. Several independent exper-
iments with different endpoints, illustrated in Table 1,
provided preliminary evidence that modulation of the
radiation response of the CNS in vivo by systemic admin-
istration of amifostine appears possible. However, addi-
tional studies are warranted to investigate the protective
effect with differing regimens of administration, more
clinically relevant fractionation regimens, and longer fol-
low-up. Various other compounds are also able to interact
with free radicals, for example glutathione. With any of
these agents, complete dose-effect curves have yet to be
generated to firmly establish their role in prevention.
DNA damage repair can be enhanced by several com-
pounds, including the growth factor insulin-like growth
factor-1 (IGF-1) [40]. As demonstrated by our group, s.c.
IGF-1 treatment for few days concomitant to irradiation
significantly increases the latent time to development of
spinal cord necrosis [41]. When combined with intrathe-
cal basic fibroblast growth factor (FGF-2) or amifostine, a
better efficacy was observed [42,43]. Dose-effect curves
were generated only for the combination of s.c. IGF-1 with
intrathecal amifostine. They suggest an increase in the
long-term radiation tolerance by approximately 7% for
single fraction irradiation. Growth factors, however,
might also influence several other mechanisms. They were
shown to prevent radiation-induced apoptosis, influence
proliferation of stem cells, neurogenesis and angiogen-
esis. Pena et al. have shown that i.v. injections of FGF-2 5
min. before, immediately after and 1 h after total body
irradiation in mice (1–20 Gy or 50 Gy) significantly
reduced the number of apoptotic vascular and glial cells in
the CNS [6]. Spinal cord experiments suggest that other
growth factors, such as platelet-derived growth factor
(PDGF) can increase the long-term radiation tolerance by
approximately 5% (two fractions of 16–20 Gy 24 h apart,
PDGF given intrathecally for 4 days starting 24 h before
the first fraction of radiation) [44]. It has recently been
suggested that i.p. injections of carbamylated erythropoi-
etin, which does not stimulate the bone marrow, reduce
the extent of brain necrosis in rats exposed to a single dose
of 100 Gy (administration for 10 days starting immedi-
ately before radiosurgery [45]). Thus, several experiments
demonstrated that delayed toxicity can be prevented by
early intervention at the time of radiation treatment. This
offers new strategies of toxicity prevention. It was also sug-
gested that growth factors have bell-shaped dose-effect
curves, i.e. high doses do not exert the best effects. More-
over, high doses of PDGF or VEGF might even cause accel-
eration of damage expression, most likely via cell-cycle-
activating signals [46]. Usually, many cell types undergo
p53-induced G1-arrest after radiotherapy to allow for
repair of treatment-induced lesions. By overriding this
mechanism with high doses of growth factors, such cells
might be forced to die, resulting in early tissue breakdown
and manifestation of damage. With delayed treatment
after 12 weeks or more, acceleration was no longer
observed, suggesting that the damage cascade might
Schematic concept of the time course of radiation-induced  reactions in cancer patients treated with ionizing radiation  via portals exposing some part of the central nervous system  (CNS) Figure 1
Schematic concept of the time course of radiation-induced 
reactions in cancer patients treated with ionizing radiation 
via portals exposing some part of the central nervous system 
(CNS). The tumor is expected to become eradicated within 
a few weeks. The severity and latency of CNS reactions are 
dose-dependent. Three different levels are shown. Acute 
CNS reactions often remain below the level of clinical detec-
tion and resolve early. A second wave of so-called late reac-
tions might develop after several months or years and after 
higher radiation doses. The upper curve with or without 
additional comorbidity shows how certain factors might influ-
ence damage progression or make intervention more diffi-
cult. The dotted line below the threshold level represents 
succesful therapeutic intervention, which was started at the 
time indicated by the arrow.
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already have reached a stage where additional manipula-
tion can not influence the outcome anymore.
Whether growth factors influence pathways leading to
neurocognitive deficits is less well studied. Fukuda et al.
suggested that erythropoietin (EPO) did not influence sin-
gle-dose irradiation-induced cell death in the dentate
gyrus of immature rodents [47]. However, neurocognitive
testing was not performed. Hossain et al. confirmed that
EPO did not modify the apoptotic response in this region
in adult mice treated with single-dose WBRT [48]. EPO
also did not reverse the inhibition of neurogenesis. How-
ever, reduced expression of inflammatory genes such as
COX-2 and ICAM-1 in the hippocampus was observed.
Several other examples of inhibition of inflammatory
reactions are available. The prophylactic use of dexameth-
asone 24 and 1 h before radiation exposure reduced the
expression of TNF-α, IL-1 and ICAM-1 [16]. In vitro, corti-
costeroids influence the function of microglial cells and
inhibit their proliferation [49]. Kondziolka et al. irradi-
ated rats with implanted cerebral glioma by SRS, either
with or without i.v. administration of U-74389G, a 21-
aminosteroid which is largely selective for endothelium
[50]. The compound reduced the development of peritu-
moral edema and of radiation-induced vascular changes
in the parts of the brain which were within the region of
the steep dose gradient outside of the target volume. Injec-
tion of an anti-ICAM-1 monoclonal antibody signifi-
cantly reduced leukocyte adhesion and vessel
permeability in a different rat model [18]. Monje et al.
observed a decrease in activated microglia and proliferat-
ing peripheral monocytes and an increase in newborn
hippocampal neurons in adult rats treated with a single
dose of 10 Gy and daily indomethacin for 2 months
beginning 2 days before brain irradiation [51]. Compared
to animals that did not receive radiation, neurogenesis
was still limited to 20–25%. No functional endpoints
were reported. Recently, Zhao et al. described a rat model
of fractionated WBRT with or without pioglitazone, an
anti-inflammatory peroxisomal proliferator-activated
receptor gamma agonist [52]. The WBRT-induced cogni-
tive impairment was best prevented by drug administra-
tion before, during, and after WBRT. Thus, preliminary
data suggest protection from neurocognitive damage or
necrosis with anti-inflammatory drugs, but dose-modifi-
cation factors have not been generated yet.
Delayed intervention/treatment of side effects/
tissue restoration
As suggested in Figure 1, delayed intervention during the
latency time circumvents the problem of tumor protec-
tion. However, trying to reverse or ameliorate side effects
will only be possible before a certain threshold level of
damage is exceeded. Higher radiation doses might require
either earlier or more efficacious interventions. In addi-
tion, comorbidity associated with perfusion disturbance
might modify damage progression. A few case reports
described successful treatment of late CNS toxicity by
hyperbaric oxygen treatment (HBO). For example, one
out of 7 patients with cognitive impairment at least 1.5
years after radiotherapy improved after 30 sessions of
HBO [53]. Patients with leukencephalopathy and moder-
ate hydrocephalus (diagnosed by intracranial pressure
monitoring) might profit from ventriculoperitoneal shunt
insertion [54]. Quality of life can be improved by support-
ive measures (cognitive training, rehabilitation, special
education etc.) and possibly by drugs prescribed for other
Table 1: Overview of experimental studies of central nervous system (CNS) radioprotection
Reference Animals CNS region RT schedule AF schedule Follow-up Results
Guelman et al. [88] Neonatal Wistar rats Cephalic end 1 × 5 Gy Subcutaneously 100 
mg/kg
30 days (90 days for 1 
endpoint)
Sign. protection
Alaoui et al. [89] Young Sprague-
Dawley rats
Whole body (brain) 1 × 2.5 Gy Intraperitoneal 75 mg/
kg
6 hours No sign. protection
Lamproglou et al. [90] Young Wistar rats Whole brain 10 × 3 Gy Intraperitoneal 37.5, 
75 and 150 mg/kg
7.5 months 37.5 mg/kg not 
effective; 150 mg/kg 
caused 34% mortality; 
75 mg/kg reduced 
memory dysfunction
Plotnikova et al. [91, 92] Adult Wistar rats Whole brain 1 × 25 Gy (earlier 
study with 40 or 60 
Gy)
Intraperitoneal 300 
mg/kg
18 months Protection against 
vascular damage, 
necrosis and death 
after 25 Gy only
Spence et al. [93] Adult F-344 rats Spinal cord 1 × 20–38 Gy Intrathecal 0.33 mg 36 weeks Protection with DMF 
1.3
Nieder et al. [94] Adult F344 rats Spinal cord 2 fractions, high dose Intrathecal 0.3 mg 12 months No sign. protection
Nieder et al. [94] Adult F344 rats Spinal cord 2 fractions, high dose Subcutaneous 200 mg/
kg
12 months Protection at 36 Gy-
level
Nieder et al. [43] Adult F344 rats Spinal cord Single fraction, high 
dose
Intrathecal 0.3 mg 
plus s.c. IGF-1
12 months Protection with DMF 
1.07
Andratschke et al. [44] Adult F344 rats Spinal cord 2 fractions, high dose Intrathecal PDGF as 
sole treatment
12 months Protection with DMF 
1.05
RT: radiotherapy; AF: amifostine; IGF-1: insulin-like growth factor-1; PDGF: platelet-derived growth factor; DMF: dose modification factorRadiation Oncology 2007, 2:23 http://www.ro-journal.com/content/2/1/23
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neurodegenerative diseases or depression [55]. Some of
these compounds such as fluoxetine increase neurogene-
sis [56]. For radionecrosis of the brain, therapeutic inter-
vention with corticosteroids or anticoagulants is
sometimes successful. They should be administered early
before the stage of cystic liquefaction. Often, surgical
resection is the only way to effectively improve the symp-
toms. Very recent, preliminary data suggest that VEGF
pathway inhibition with bevacizumab might be able to
reduce both the MRI abnormalities associated with necro-
sis and the dexamethasone requirement [57]. These find-
ings lend support to the preclinical spinal cord
radionecrosis data [31].
Ramipril, an inhibitor of angiotensin-converting enzyme,
was studied in a rat model of optic neuropathy 6 months
after irradiation with both functional and histological
endpoints [58]. Continuous daily drug treatment started
already 2 weeks after irradiation. Encouraging results for
both endpoints were reported. However, only a single
radiation dose level was examined. Hornsey et al. evalu-
ated vasoactive drugs administered from 17 weeks
onwards after single-dose irradiation of rat spinal cord
[59]. Dipyridamol increased the median latent time from
167 to 195 days at the level of the ED100 and from 193 to
240 days at the ED80. Moreover, the better effectiveness at
lower radiation doses led to an increase in ED50 by 2–3 Gy
(approximately 10%).
Transplantation of stem cells or stimulation of the endog-
enous stem cell compartment, e.g., by growth factor appli-
cation might also offer exciting prospects. In principle,
mature functional cells can be generated by proliferation
and differentiation from stem, progenitor, and precursor
cells or by recovery and repair of damage in already exist-
ing cells which then continue to survive. Important differ-
ences exist between embryonic, umbilical cord blood, and
various types of adult stem cells. All of these, however, are
capable of self-renewal, a process by which stem cells
divide to generate one (asymmetric division) or two (sym-
metric division) daughter stem cells, are proliferative, and
are multipotent for the different cell lineages. Besides of
killing stem cells, ionizing radiation could also exert
adverse effects if it would directly or indirectly change the
programming and behaviour of these cells, e.g., by trigger-
ing generation of glial cells only or by maintaining their
own stem cell pool without generation of differentiated
progeny. Stem cell maintenance, prevention of premature
senescence and apoptosis, and differentiation in the
mammalian CNS are complex and well regulated, e.g., by
Sonic Hedgehog, Polycomb family members, cell cycle
regulators, and environmental factors in the stem cell
niche [60,61].
Both hematopoietic and neural stem cells might be bene-
ficial for CNS regeneration. Neural stem cells can be
divided into two different subsets, i.e. CNS stem cells and
neural crest stem cells. The latter give rise to neurons and
glia of the peripheral nervous system and other connective
cell types. The subventricular zones (SVZ) adjacent to the
lateral ventricles contain a mosaic of immature multipo-
tential, bipotential, and unipotential neural CNS stem
cells as well as progenitors at different stages of lineage
restriction (Figure 2). Other regions in the adult CNS, incl.
hippocampus, optic nerve and spinal cord, contain at
least certain types of precursors (reviewed by Emsley et al.
[62]). Several growth factors instruct lineage differentia-
tion. In addition, there are switches, such as Notch activa-
tion, that determine neurogenesis, which normally occurs
first, and initiate gliogenesis. Some of these CNS precursor
cells are highly sensitive to ionizing radiation and
undergo apoptosis, as already discussed. Interestingly,
neural stem cells are less prone to apoptosis as progeni-
tors, e.g. late oligodendrocyte progenitors (reviewed by
Romanko et al. [63]). Tada et al. showed that 24 h after
irradiation of rat brains significant reductions occur in
total cell number, and in the number of proliferating cells
and immature neurons in the SVZ [64]. With higher radi-
ation doses no relevant repopulation of the SVZ was
observed for at least 6 months. Obviously, surviving stem
cells do not receive the proper signals to initiate tissue
recovery after irradiation or maybe surrounding support-
ive elements are lost (see inflammatory and vascular
changes reviewed earlier). Another limiting factor for
endogenous stem cells is the fact that they undergo cell-
intrinsic changes in developmental or neuronal subtype
potential over time [65], possibly reducing their capacity
to form neurons and biasing the types of neurons they can
make. It can not be excluded that radiation-induced glio-
sis might prevent generation of the required cell types
[61]. Furthermore, activation of both neural and endothe-
lial/vascular cell lineages might be required to achieve
durable success. Neural stem cells grown with endothelial
cells in vitro underwent symmetric, proliferative divisions,
in contrast to the asymmetric pattern seen in control con-
ditions [66]. Endothelial cells secrete factors such as FGF-
2 that influence self-renewal and neurogenic potential.
While the stem cells generated neurons, astrocytes, and
oligodendrocytes upon endothelial cell removal, no
endothelial progeny was generated.
Immature cells are able to migrate tangentially and radi-
ally within the CNS for a limited distance, possibly lead-
ing to regeneration of small lesions from the surrounding
healthy tissue [67]. Astrocytes and endothelial cells up-
regulate chemokines such as stromal cell-derived factor
(SDF)-1α after injury. As shown by Imitola et al., neural
stem cells by virtue of their expression of chemokine
receptors migrate to sources of SDF-1α and home to theRadiation Oncology 2007, 2:23 http://www.ro-journal.com/content/2/1/23
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injury-induced stem cell niches [68]. Migration also
depends on adhesion and extracellular matrix molecules.
Without manipulation, there appears to be limited
directed cell migration and replacement from endog-
enous cell pools, e.g., in the SVZ. Growth factors might
represent potential tools for manipulation. Different
experimental CNS damage models suggest that IGF-1
causes an increase in oligodendrocyte numbers in previ-
ously damaged areas of the rat spinal cord [69]. IGF-1
reduces the permeability of the blood-brain barrier and
has been found to influence the restoration of neurogen-
esis in the adult and aging hippocampus [70]. Granulo-
cyte colony-stimulating factor (G-CSF) also induced
proliferation and differentiation of neural precursors and
endothelial cell proliferation in adult rat brain in vivo,
most likely via VEGF interaction [71]. Brain-derived neu-
rotrophic factor (BDNF) also leads to recruitment of
endothelial cells and increase of capillary density [72].
However, even in theory finding the right dose, timing
and maybe combination and sequence of different growth
factors in an individual patient appears very challenging,
not to mention that growth factor doses in some experi-
mental conditions are too high for human application.
Limited time intrathecal administration of VEGF or PDGF
for two weeks starting 8–16 weeks after rat spinal cord
irradiation was not effective in preventing necrosis (own
unpublished data), underlining that relatively simple
interventions aiming at the surviving endogenous cell
population might not be the preferable approach in a
complexly altered CNS environment.
As an alternative, exogenous neural stem cells might
induce tissue regeneration. Such cells can even be engi-
neered to manipulate their own microenvironment, as
shown for example by Zhu et al. who transfected fetal neu-
ral stem cells with VEGF gene [73]. After transplantation,
the stem cells migrated and expressed VEGF during the
early time after transplantation. Later, some of them dif-
ferentiated to neurons. If precursor cells rather than stem
cells are transplanted into neurogenic regions, they can
differentiate into neurons in a region-specific manner
[74]. When transplanted outside the neurogenic regions,
they might generate only glia [62]. Thus, neurogenesis is
dependent on a permissive microenvironment. This again
leads to the question of how neurogenic permissiveness
can be induced or modified because donor cells, whatever
their source, must interact with an extremely complex
CNS environment in order to integrate appropriately. The
same holds true for the other main endpoint, i.e. radiation
necrosis. O-2A progenitor cells transplanted into irradi-
ated rat spinal cord were shown to divide, migrate and
contribute to remyelination [75]. Rezvani et al. used neu-
ral stem cell transplantation to protect rats against spinal
cord necrosis [76]. Their results were encouraging, how-
ever, follow-up was shorter than 12 months. Furthermore,
they conducted the study in younger rats whose immature
spinal cord might react differently.
What results can be expected from transplanted non-neu-
ral cells? A detailed description of this issue is beyond the
scope of this paragraph, as recent reviews provide a lot of
background information, e.g. [77]. Umbilical cord blood-
derived cells have been identified in the CNS and
endothelium [78] and were beneficial in a mouse model
of amyotrophic lateral sclerosis [79]. It has been sug-
gested, however, that hematopoietic stem cells maintain
lineage fidelity in the brain and do not adopt neural cell
fates [80] or transdifferentiate [81]. We are not aware of
studies having addressed this question specifically in irra-
diated CNS. A French group transplanted human mesen-
chymal stem cells into mice subjected to sublethal total
body irradiation (TBI) with or without superimposed
local fields [82,83]. Without irradiation, these stem cells
did not engraft in the brain within 15 days (maximum
observation time). After TBI increased engraftment was
detected. In a model of mouse skin irradiation, beneficial
effects of cultured bone marrow mesenchymal stem cells
on lesion healing were suggested too [84]. With regard to
experimental conditions, it has to be emphasized that
observations in precursor research in general might be
site- and condition-specific and thus hard to generalize.
Some of the observations still create considerable contro-
versy (fact or artifact, as reviewed by Krabbe et al. [85]). It
should also be mentioned that stimulation of precursor
cell proliferation does not necessarily lead to sufficient
numbers of those differentiated cells that keep the organ
Growth factors influence several steps of neurogenesis Figure 2
Growth factors influence several steps of neurogenesis. NSC: 
neural stem cell, NPC: neural progenitor cell, GPC: glial pro-
genitor cell, FGF-2: basic fibroblast growth factor, EGF: epi-
dermal growth factor, CNTF: ciliary neurotrophic factor, 
EPO: erythropoietin, PDGF: platelet-derived growth factor, 
IGF-1: insulin-like growth factor-1, BMP-2: bone morphoge-
netic protein-2, BDNF: brain-derived neurotrophic factor, 
T3: thyroid hormone
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functional. This is emphasized by observations of lack of
differentiation of O-2A cells into oligodendrocytes [86]
and differentiation of endothelial progenitors into
smooth muscle cells, potentially increasing the thickness
of the blood vessel wall [87] after treatment with PDGF-
BB. It is also clear that true neuronal integration depends
on many complex variables and progressive events.
Conclusion
Although a large body of research on radiation-induced
CNS toxicity is still necessary, one can envision a scenario
with individually tailored strategies where patients with
comorbidity resulting in impaired regeneration reserve
capacity might be considered for toxicity prevention,
while others might be "salvaged" by delayed interventions
that circumvent the problem of normal tissue specificity.
Given the complexity of radiation-induced changes, sin-
gle target interventions might not suffice. Intervention
might vary by patient age, elapsed time from radiotherapy
and toxicity type. Potential components include drugs
that target neurodegeneration or perfusion/hypoxia, cell
transplantation (into the CNS itself, the blood stream, or
both) and creation of reparative signals and a permissive
microenvironment, e.g., for cell homing. Without manip-
ulation of the stem cell niche either by cell transfection or
addition of appropriate chemokines and growth factors
and by providing normal perfusion of the affected region,
durable success of cell-based strategies is hard to imagine.
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